Molecular mechanisms underlying oesophageal cancer development triggered by chronic alcohol consumption

Abstract

This review explores the mechanisms underlying alcohol-induced oesophageal carcinogenesis, including DNA damage, oxidative stress, and nutritional deficiencies. Alcohol metabolism primarily involves alcohol dehydrogenase (ADH) converting ethanol to acetaldehyde, which can cause DNA damage, inhibit repair mechanisms, and form DNA adducts thus inhibiting DNA replication. Plus, it delves into the epidemiological evidence, genetic susceptibility, epigenetic modifications, biomarkers, and preventive strategies associated with alcohol-related oesophageal cancers. Consumption of alcohol increases the risk of gastroesophageal reflux disease thus compromising mucosal integrity of the oesophagus as dysregulation of cytokines such as IL-18, TNFA, GATA3, TLR4, and CD68 expands the intercellular spaces of epithelial cells. Genetic variants, such as ADH1B rs1229984 and ALDH2 rs671, significantly influence susceptibility to alcohol-related oesophageal cancers, with these variations affecting acetaldehyde metabolism and cancer risk. Understanding these factors is crucial for early detection, effective treatment, and the development of targeted prevention strategies. Biomarkers, such as miRNA and metabolite markers, offer non-invasive methods for early detection, while advanced endoscopic techniques provide better diagnostic accuracy. Pharmacological interventions, such as statins and proton pump inhibitors, also show potential for reducing cancer progression in high-risk individuals. Despite advances, late-stage oesophageal cancer diagnoses are still common, highlighting the need for better screening and prevention. Further research, including this study, should aim to improve early detection, personalise prevention, and explore new treatments to reduce cases and enhance outcomes in alcohol-related oesophageal cancers.

Keywords

alcohol / metabolism / molecular mechanism / oesophageal cancer

References

[1] SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[2] LanderS, LanderE, GibsonMK. Esophageal cancer: overview, risk factors, and reasons for the rise. Current Gastroenterology Reports. 2023;25(11):275-279. 2023/11/01.

[3] PetrilloA, SmythEC. Immunotherapy for squamous esophageal cancer: a review. J Pers Med. 2022;12(6).

[4] LinY, Totsuka Y, ShanB, et al. Esophageal cancer in high-risk areas of China: research progress and challenges. Ann Epidemiol. 2017;27(3):215-221.

[5] LiuCQ, MaYL, QinQ, et al. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 2023;14(1):3-11.

[6] MorganE, Soerjomataram I, RumgayH, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163(3):649-658. e2.

[7] AbnetCC, ArnoldM, WeiWQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360-373.

[8] SheikhM, Roshandel G, McCormackV, MalekzadehR. Current status and future prospects for esophageal cancer. Cancers (Basel). 2023;15(3).

[9] WatersJK, ReznikSI. Update on management of squamous cell esophageal cancer. Current Oncology Reports. 2022;24(3):375-385. 2022/03/01.

[10] MizumotoA, OhashiS, HirohashiK, Amanuma Y, MatsudaT, MutoM. Molecular mechanisms of acetaldehyde-mediated carcinogenesis in squamous epithelium. Int J Mol Sci. 2017;18(9):1943.

[11] SeitzHK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7(8):599-612.

[12] JohnsonCH, GollaJP, DioletisE, et al. Molecular mechanisms of alcohol-induced colorectal carcinogenesis. Cancers (Basel). 2021;13(17):4404.

[13] HoesL, DokR, VerstrepenKJ, NuytsS. Ethanol-induced cell damage can result in the development of oral tumors. Cancers (Basel). 2021;13(15):3846.

[14] BrooksPJ. DNA damage, DNA repair, and alcohol toxicity-a review. Alcohol Clin Exp Res. 1997;21(6):1073-1082.

[15] TohY, OkiE, OhgakiK, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15(2):135-144.

[16] KamranU, ToweyJ, KhannaA, Chauhan A, RajoriyaN, HoltA. Nutrition in alcohol-related liver disease: physiopathology and management. World J Gastroenterol. 2020;26(22):2916-2930.

[17] LieberCS, Alcohol and nutrition;an overview. Alcohol Health & Research World;1989. p. 197.

[18] LieberCS. Relationships between nutrition, alcohol use, and liver disease. Alcohol Res Health. 2003;27(3):220-231.

[19] LiJ, XuJ, ZhengY, et al. Esophageal cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2021;33(5):535-547.

[20] UhlenhoppDJ, ThenEO, SunkaraT, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010-1021.

[21] RumgayH, MurphyN, FerrariP, Soerjomataram I. Alcohol and cancer: epidemiology and biological mechanisms. Nutrients. 2021;13(9).

[22] VioqueJ, BarberX, BolumarF, et al. Esophageal cancer risk by type of alcohol drinking and smoking: a case-control study in Spain. BMC Cancer. 2008;8:221.

[23] PandeyaN, Williams G, GreenAC, WebbPM, Whiteman DC. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology. 2009;136(4):1215-1224. e1-2.

[24] VogtCD, Panoskaltsis-Mortari A. Tissue engineering of the gastroesophageal junction. J Tissue Eng Regen Med. 2020;14(6):855-868.

[25] WoodlandP, SifrimD. Esophageal mucosal integrity in nonerosive reflux disease. J Clin Gastroenterol. 2014;48(1):6-12.

[26] LucaM, YaojieF, YvesH, et al. Alcohol-associated bowel disease: new insights into pathogenesis. eGastroenterology. 2023;1(1):e100013.

[27] KwonMJ, KangHS, ChoiHG, et al. Risk for esophageal cancer based on lifestyle factors-smoking, alcohol consumption, and body mass index: insight from a South Korean Population Study in a low-incidence area. J Clin Med. 2023;12(22):7086.

[28] TranCL, HanM, KimB, ParkEY, KimYI, Oh JK. Gastroesophageal reflux disease and risk of cancer: findings from the Korean National Health Screening Cohort. Cancer Med. 2023;12(18):19163-19173.

[29] MezaV, ArnoldJ, DíazLA, et al. alcohol consumption: medical implications, the liver and beyond. Alcohol Alcoholism. 2022;57(3):283-291.

[30] TanJ, LiL, HuangX, et al. Associations between gastro-oesophageal reflux disease and a range of diseases: an umbrella review of systematic reviews and meta-analyses. BMJ Open. 2020;10(12):e038450.

[31] MaevIV, LivzanMA, MozgovoiSI, Gaus OV, BordinDS. Esophageal mucosal resistance in reflux esophagitis: what we have learned so far and what remains to be learned. Diagnostics (Basel). 2023;13(16).

[32] MorozovS, Sentsova T. Local inflammatory response to gastroesophageal reflux: association of gene expression of inflammatory cytokines with esophageal multichannel intraluminal impedance-pH data. World J Clin Cases. 2022;10(26):9254-9263.

[33] MaevIV, LivzanMA, MozgovoiSI, Gaus OV, BordinDS. Esophageal mucosal resistance in reflux esophagitis: what we have learned so far and what remains to be learned. Diagnostics. 2023;13(16):2664.

[34] MoonwiriyakitA, Pathomthongtaweechai N, SteinhagenPR, ChantawichitwongP, Satianrapapong W, PongkorpsakolP. Tight junctions: from molecules to gastrointestinal diseases. Tissue Barriers. 2023;11(2):2077620.

[35] ParkD, JeonWJ, YangC, Castillo DR. Advancing esophageal cancer treatment: immunotherapy in neoadjuvant and adjuvant settings. Cancers. 2024;16(2):318.

[36] KanT, Meltzer SJ, MicroRNAs in Barrett’s esophagus and esophageal adenocarcinoma. Current Opinion in Pharmacology. 2009;9(6):727-732.

[37] MarabottoE, Pellegatta G, SheijaniAD, et al. Prevention strategies for esophageal cancer-an expert review. Cancers (Basel). 2021;13(9).

[38] ZhangB, PengYH, LuoY, et al. Relationship between esophageal squamous cell carcinoma risk and alcohol-related ALDH2 and ADH1B polymorphisms: evidence from a meta-analysis and Mendelian randomization analysis. Cancer Med. 2023;12(20):20437-20449.

[39] ImPK, YangL, KartsonakiC, et al. Alcohol metabolism genes and risks of site-specific cancers in Chinese adults: an 11-year prospective study. Int J Cancer. 2022;150(10):1627-1639.

[40] ChenS, CaoR, LiuC, TangW, KangM. Investigation of IL-4, IL-10, and HVEM polymorphisms with esophageal squamous cell carcinoma: a case-control study involving 1929 participants. Biosci Rep. 2020;40(8).

[41] ChoYA, KimJ. Association of IL4, IL13, and IL4R polymorphisms with gastrointestinal cancer risk: a meta-analysis. J Epidemiol. 2017;27(5):215-220.

[42] CabantousS, RanqueS, PoudiougouB, et al. Genotype combinations of two IL4 polymorphisms influencing IL-4 plasma levels are associated with different risks of severe malaria in the Malian population. Immunogenetics. 2015;67(5-6):283-288.

[43] EltayebMM, AliMM, OmarSM, Mohamed NS, AdamI, HamdanHZ. Gene polymorphisms of cyclin-dependent kinase inhibitor and matrix metalloproteinase-9 in Sudanese patients with esophageal squamous cell carcinoma. Mol Genet Genomic Med. 2022;10(12):e2074.

[44] SharpAN, Heazell AE, BaczykD, et al. Preeclampsia is associated with alterations in the p53-pathway in villous trophoblast. PLoS One. 2014;9(1):e87621.

[45] el-DeiryWS, HarperJW, O’ConnorPM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54(5):1169-1174.

[46] AmaraFM, ChenFY, WrightJA. Defining a novel cis element in the 3’-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: role in transforming growth factor-beta 1 induced mRNA stabilization. Nucleic Acids Res. 1995;23(9):1461-1147.

[47] FanH, Villegas C, HuangA, WrightJA. Suppression of malignancy by the 3’untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res. 1996;56(19):4366-4369.

[48] LiG, LiuZ, SturgisEM, et al. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2005;26(9):1596-1602.

[49] RoninsonIB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1):association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002;179(1):1-14.

[50] AllisCD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487-500.

[51] WuL, ZhangY, RenJ. Epigenetic modification in alcohol use disorder and alcoholic cardiomyopathy: from pathophysiology to therapeutic opportunities. Metabolism. 2021;125:154909.

[52] López-MorenoJA, Marcos M, Calleja-CondeJ, et al. Histone deacetylase gene expression following binge alcohol consumption in rats and humans. Alcohol Clin Exp Res. 2015;39(10):1939-1950.

[53] BohnsackJP, PandeySC. Histone modifications, DNA methylation, and the epigenetic code of alcohol use disorder. Int Rev Neurobiol. 2021;156:1-62.

[54] PandeySC, UgaleR, ZhangH, Tang L, PrakashA. Brain chromatin remodeling: a novel mechanism of alcoholism. J Neurosci. 2008;28(14):3729-3737.

[55] JosephA, RajaS, KamathS, et al. Esophageal adenocarcinoma: a dire need for early detection and treatment. Cleveland Clinic Journal of Medicine. 2022;89(5):269.

[56] RaiV, AbdoJ, AgrawalDK. Biomarkers for early detection, prognosis, and therapeutics of esophageal cancers. International Journal of Molecular Sciences. 2023;24(4):3316.

[57] FassanM, Realdon S, CascioneL, et al. Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett’s carcinogenesis. Pathol Res Pract. 2020;216(5):152907.

[58] LinZ, ChenY, LinY, et al. Potential miRNA biomarkers for the diagnosis and prognosis of esophageal cancer detected by a novel absolute quantitative RT-qPCR method. Scientific Reports. 2020:20065.

[59] XuG, YangY, YangJ, et al. Screening and identification of miR-181a-5p in oral squamous cell carcinoma and functional verification in vivo and in vitro. BMC Cancer. 2023;23(1):162.

[60] LiJ, ShenJ, ZhaoY, et al. Role of miR 181a 5p in cancer (Review). Int J Oncol. 2023;63(4):108.

[61] SunY, LiuW, SuM, et al. Purine salvage-associated metabolites as biomarkers for early diagnosis of esophageal squamous cell carcinoma: a diagnostic model-based study. Cell Death Discov. 2024;10(1):139.

[62] SebestaI, Genetic disorders resulting in hyper-or hypouricemia. Adv Chronic Kidney Dis. 2012;19(6):398-403.

[63] MevesV, Behrens A, PohlJ. Diagnostics and early diagnosis of esophageal cancer. Viszeralmedizin. 2015;31(5):315-318.

[64] NoordzijIC, Curvers WL, SchoonEJ, Endoscopic resection for early esophageal carcinoma. J Thorac Dis. 2019;11(Suppl 5):S713-s722.

[65] MaK, KalraA, TsaiH-L, et al. Accurate nonendoscopic detection of esophageal squamous cell carcinoma using methylated DNA biomarkers. Gastroenterology. 2022;163(2):507-509. e2.

[66] PanY, HeL, ChenW, Yang Y. The current state of artificial intelligence in endoscopic diagnosis of early esophageal squamous cell carcinoma. Front Oncol. 2023;13:1198941.

[67] VisaggiP, Barberio B, GhisaM, et al. Modern diagnosis of early esophageal cancer: from blood biomarkers to advanced endoscopy and artificial intelligence. Cancers (Basel). 2021;13(13). 3162.

[68] WanderP, TokarJL. Endoscopic management of early esophageal cancer: a literature review. Annal Esophagus. 2021;638-646.

[69] NucciD, MarinoA, RealdonS, Nardi M, FatigoniC, LifestyleGianfrediV. WCRF/AICR recommendations, and esophageal adenocarcinoma risk: a systematic review of the literature. Nutrients. 2021;13(10):3525.

[70] SchulpenM, Peeters PH, van den BrandtPA. Mediterranean diet adherence and risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study. Gastric Cancer. 2019;22(4):663-674.

[71] ZhangX, Anandasabapathy S, AbramsJ, OthmanM, BadrHJ. Lifestyle risk factors, quality of life, and intervention preferences of Barrett’s esophagus patients: a prospective cohort study. Global Adv Health Med. 2021;10:21649561211001346.

[72] PatelAV, Friedenreich CM, MooreSC, et al. American College of Sports Medicine Roundtable Report on physical activity, sedentary behavior, and cancer prevention and control. Med Sci Sports Exerc. 2019;51(11):2391-2402.

[73] SinghS, Devanna S, Edakkanambeth VarayilJ, MuradMH, Iyer PG. Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2014;14:101.

[74] KrestyLA, MorseMA, MorganC, et al. Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries. Cancer Res. 2001;61(16):6112-6119.

[75] SinghS, SinghAG, SinghPP, Murad MH, IyerPG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(6):620-629.

[76] BealesILP, Hensley A, LokeY. Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol and Therapeutics. 2013;4(3):69.

[77] LiuC, ChenH, HuB, ShiJ, ChenY, Huang K. New insights into the therapeutic potentials of statins in cancer. Front Pharmacol. 2023;14:1188926.

[78] CalpinGG, DaveyMG, DonlonNE. Management of early oesophageal cancer: an overview. World J Gastrointest Surg. 2024;16(5):1255-1258.

[79] HaradaK, RogersJE, IwatsukiM, Yamashita K, BabaH, AjaniJA. Recent advances in treating oesophageal cancer. F1000Res. 2020:9.

[80] BleibergH, ConroyT, PaillotB, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216-qw20.

[81] LordickF, Mariette C, HaustermansK, ObermannováR, Arnold D. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):v50-v57.

[82] PuhrHC, PragerGW, Ilhan-MutluA, How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789.

[83] van RossumPSN, Mohammad NH, VleggaarFP, van HillegersbergR. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15(4):235-249.

[84] BregniG, BeckB. Toward targeted therapies in oesophageal cancers: an overview. Cancers (Basel). 2022;14(6).

[85] ThriftAP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021;18(6):432-443.

[86] DavorenSL. Legal interventions to reduce alcohol-related cancers. Public Health. 2011;125(12):882-888.

[87] AustokerJ. Reducing alcohol intake. BMJ. 1994;308(6943):1549-1552.

[88] WhitemanDC. Esophageal cancer: priorities for prevention. Curr Epidemiol Rep. 2014;1(3):138-148.

[89] LanderS, LanderE, GibsonMK. Esophageal cancer: overview, risk factors, and reasons for the rise. Curr Gastroenterol Rep. 2023;25(11):275-279.

[90] McCullochP, BrownP, MartinB, Williams E. The effects of an awareness-raising program for patients and primary care physicians on the early detection of gastro-oesophageal cancer. Surgery. 2003;133(2):154-161.

[91] MiyakoS, KomaY-i, NakanishiT, et al. Periostin in cancer-associated fibroblasts promotes esophageal squamous cell carcinoma progression by enhancing cancer and stromal cell migration. Am J Pathol. 2024;194(5):828-848.

[92] IshibashiY, Mochizuki S, HoriuchiK, et al. Periostin derived from cancer-associated fibroblasts promotes esophageal squamous cell carcinoma progression via ADAM17 activation. Biochim Biophys Acta Mol Basis Dis. 2023;1869(5):166669.

[93] QuHT, LiQ, HaoL, et al. Esophageal cancer screening, early detection and treatment: current insights and future directions. World J Gastrointest Oncol. 2024;16(4):1180-1191.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.